Cargando…

The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain

Nerve growth factor (NGF) belongs to the neurotrophin family and plays a fundamental role in the endurance of sensory and sympathetic neurons during embryogenesis. NGF, by interacting with tropomyosin receptor kinase A receptor (TrkA), modulates the pain pathway through the enhancement of the neurot...

Descripción completa

Detalles Bibliográficos
Autores principales: Bimonte, Sabrina, Cascella, Marco, Forte, Cira Antonietta, Esposito, Gennaro, Cuomo, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253925/
https://www.ncbi.nlm.nih.gov/pubmed/34234542
http://dx.doi.org/10.2147/JPR.S302004
_version_ 1783717619708198912
author Bimonte, Sabrina
Cascella, Marco
Forte, Cira Antonietta
Esposito, Gennaro
Cuomo, Arturo
author_facet Bimonte, Sabrina
Cascella, Marco
Forte, Cira Antonietta
Esposito, Gennaro
Cuomo, Arturo
author_sort Bimonte, Sabrina
collection PubMed
description Nerve growth factor (NGF) belongs to the neurotrophin family and plays a fundamental role in the endurance of sensory and sympathetic neurons during embryogenesis. NGF, by interacting with tropomyosin receptor kinase A receptor (TrkA), modulates the pain pathway through the enhancement of the neurotrophic and nociceptor functions. Moreover, it has been demonstrated that NGF is upregulated in patients with chronic pain syndromes, which are difficult to treat. Thus, new non-pharmacological approaches, based on the use of different species-specific monoclonal antibodies (mAbs) targeting the NGF pathway, have been tested for the treatment of chronic pain in preclinical and clinical studies. With regard to preclinical investigations, anti-NGF mAbs have been used for the management of osteoarthritis (OA) and chronic low back pain animal models, with encouraging results. Moreover, anti-NGF mAb therapy is effective in animal models of neuropathic cancer pain. As regards patients with OA, although phase II and phase III clinical trials with tanezumab led to pain reduction, the safety was not observed in all these patients. Here, we review the preclinical and clinical studies on anti-NGF mAb therapy in chronic syndromes, dissect the role of NGF in pain transduction, and highlight the use of anti-NGF mAbs in humans.
format Online
Article
Text
id pubmed-8253925
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82539252021-07-06 The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain Bimonte, Sabrina Cascella, Marco Forte, Cira Antonietta Esposito, Gennaro Cuomo, Arturo J Pain Res Review Nerve growth factor (NGF) belongs to the neurotrophin family and plays a fundamental role in the endurance of sensory and sympathetic neurons during embryogenesis. NGF, by interacting with tropomyosin receptor kinase A receptor (TrkA), modulates the pain pathway through the enhancement of the neurotrophic and nociceptor functions. Moreover, it has been demonstrated that NGF is upregulated in patients with chronic pain syndromes, which are difficult to treat. Thus, new non-pharmacological approaches, based on the use of different species-specific monoclonal antibodies (mAbs) targeting the NGF pathway, have been tested for the treatment of chronic pain in preclinical and clinical studies. With regard to preclinical investigations, anti-NGF mAbs have been used for the management of osteoarthritis (OA) and chronic low back pain animal models, with encouraging results. Moreover, anti-NGF mAb therapy is effective in animal models of neuropathic cancer pain. As regards patients with OA, although phase II and phase III clinical trials with tanezumab led to pain reduction, the safety was not observed in all these patients. Here, we review the preclinical and clinical studies on anti-NGF mAb therapy in chronic syndromes, dissect the role of NGF in pain transduction, and highlight the use of anti-NGF mAbs in humans. Dove 2021-06-28 /pmc/articles/PMC8253925/ /pubmed/34234542 http://dx.doi.org/10.2147/JPR.S302004 Text en © 2021 Bimonte et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Bimonte, Sabrina
Cascella, Marco
Forte, Cira Antonietta
Esposito, Gennaro
Cuomo, Arturo
The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain
title The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain
title_full The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain
title_fullStr The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain
title_full_unstemmed The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain
title_short The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain
title_sort role of anti-nerve growth factor monoclonal antibodies in the control of chronic cancer and non-cancer pain
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253925/
https://www.ncbi.nlm.nih.gov/pubmed/34234542
http://dx.doi.org/10.2147/JPR.S302004
work_keys_str_mv AT bimontesabrina theroleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT cascellamarco theroleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT forteciraantonietta theroleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT espositogennaro theroleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT cuomoarturo theroleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT bimontesabrina roleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT cascellamarco roleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT forteciraantonietta roleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT espositogennaro roleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain
AT cuomoarturo roleofantinervegrowthfactormonoclonalantibodiesinthecontrolofchroniccancerandnoncancerpain